This chapter should be cited as follows: Under review - Update due 2018
Bischoff, F, Simpson, J, Glob. libr. women's med.,
(ISSN: 1756-2228) 2008; DOI 10.3843/GLOWM.10363

Genetics

Genetics of Endometriosis

Farideh Z. Bischoff, PhD
Assistant Professor, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
Joe Leigh Simpson, MD
Ernst W. Bertner Chairman and Professor, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas

INTRODUCTION

Endometriosis is a common disease defined as the growth of endometrial tissue outside the uterine cavity that often results in a vast array of problems, including dyspareunia, dysmenorrhea, pelvic pain, and infertility. The true incidence of endometriosis is unknown, but reported estimates normally range from 10% to 15% for all women of reproductive age and from 25% to 35% for women who are infertile.1 The histopathology of endometriosis is variable and dependent on the site of growth. Ovaries, uterosacral ligaments, retrovaginal septum, and pelvic peritoneum are principal sites. Because of the heterogeneity of this disease, development of a reliable classification system to aid in diagnosis of disease stage and therapy has been difficult. Currently, the disease is classified into stages ranging from mild to moderate to severe based on the size, number, and depth of endometriotic lesions.2 However, these parameters do not always correlate with severity of symptoms (e.g., pain or infertility or both). Treatment involves surgical resection or use of various hormonal-based regimens (e.g., progestogens, Danocrine, gonadotropin-releasing hormone [GNRH] agonists).

Retrograde menstruation is believed to be a common mechanism involving backward flow of menstrual blood and uterine tissue that is refluxed through the Fallopian tubes into the peritoneal space. There have been many reports in support of this mechanism.3,4,5 However, although most women are believed to exhibit retrograde menstruation, only some have endometriosis.6 Therefore, the development of endometriosis in only a select percentage of women implies increased susceptibility to disease.

FAMILIAL AGGREGATES

Endometriosis has long been suspected of familial tendencies. Following the questionnaire survey of Ranney7 reported in 1971, Simpson and coworkers8 conducted the first formal genetic study. A total of 123 probands with histologically verified endometriosis were identified. Nine (5.9%) of 153 female siblings older than 18 years had endometriosis; 10 (8.1%) of the 123 mothers were affected. Only 1% of the patients' husbands' first-degree relatives (control subjects) had endometriosis. Of two sets of monozygotic (MZ) twins, one was concordantly affected. Women with an affected sibling or parent were more likely to have severe than mild or moderate endometriosis.9 Severe endometriosis was present in 11 (61%) of 18 probands having an affected first-degree relative. Severe endometriosis was present in only 25 (23%) of 105 having no affected first-degree relative.

Studies by other investigators have confirmed these results. Lamb and coworkers10 used questionnaires received from 491 members of the Endometriosis Association within the United States. Positive family history was reported by 18% of respondents. Of the 66 women who were evaluated in greater detail, 43 returned a detailed questionnaire completed as well by a friend (control subject). Endometriosis was present in 6.2% in mothers of proband and 3.8% in sisters; endometriosis was reported in fewer than 1% in first-degree relatives of friends. The frequency in second-degree relatives was 0.4% in grandmothers and 3.1% in aunts. In this study, most (93%) affected relatives were in the maternal lineage. A pitfall of this study is that no attempts were made to confirm the diagnosis in relatives believed to be affected; however, members of the Endometriosis Association can be assumed to be knowledgeable concerning the disorder.

In Norway, Moen and Magnus11 conducted a study similar to that of Simpson and colleagues.8 Among 522 informative cases, 3.9% of mothers and 4.8% of sisters had endometriosis; only 0.6% of sisters of women not having endometriosis (control subjects undergoing laparoscopy for other reasons) were affected. In this study, either endometriosis or adenomyosis constituted the basis for diagnosis. Mothers were far more likely to have adenomyosis than affected sisters. As in the U.S. cases of Simpson and coworkers8 and Malinak and coworkers,9 familial cases in Norway proved more likely to show severe endometriosis than were nonfamilial cases. In another report from the same Norwegian center, eight MZ twins were observed among 515 endometriosis cases.12 Six of the eight sets were concordant, and in three cases, mothers also were affected.

In the United Kingdom, Coxhead and Thomas13 reported a sixfold increase frequency of endometriosis among first-degree relatives. Of 64 patients confirmed to have endometriosis, 6 (9.4%) had an affected first-degree relative. Among the 128 control women, only 2 (1.6%) reported to have a first-degree relative affected with endometriosis. More recently, dos Reis and coworkers14 reported 7 (8.6%) of first-degree relatives of 81 probands to be affected compared with no relatives of 43 control subjects.

Investigations have been initiated to solicit familial cases for linkage studies by performing sibling pair analysis using DNA polymorphic variants. Recurrence data cannot be derived because of the selection biases, but these studies nonetheless confirmed that familial aggregates are not infrequent.15,16,17 The OXGENE (Ox ford Endometriosis Gene) group recorded receipt of samples from 19 mother-daughter pairs and 56 sibling pairs.15 In 18 families, 3 or more relatives in more than 1 generation were observed. All but 2 of 16 MZ twin pairs have been concordant for endometriosis.18 A similar study in Iceland also yielded 15 familial aggregates.19 Of interest is that Kennedy and colleagues20,21 recommend magnetic resonance imaging to diagnose endometriosis. Endometriosis was found on magnetic resonance imaging in 5 (14%) of 14 first-degree relatives and 1 (8%) of 12 other relatives.

Higher concordance for MZ than DZ twins has been observed.12,15,22 In addition, endometriosis detected in the context as a cause for surgical menopause is more highly correlated in MZ twins than in DZ twins (r = 0.52 versus r = 0.19).22 Finally, catamenial pneumothorax was reported in two sisters having pelvic endometriosis.23 Pneumothorax occurred on the right, the usual site.

GENETIC MECHANISM

Endometriosis is clearly heritable, but the precise mechanism or mechanisms remain unclear. Magnitude of the increased risk (5% to 8% of first-degree relatives) is more reminiscent of polygenic/multifactorial tendencies than a single mutant gene. However, this recurrence risk is higher than the 2% to 5% expected risk for polygenic inheritance. The frequency of affected relatives might be even higher if one could directly measure a gene product or products. Although Mendelian mechanisms cannot be excluded, polygenic inheritance seems more likely if one assumes all endometriosis is a single disorder. If it is, the increased severity in familial cases is also consistent with predictions based on a polygenic model. Such a model predicts that the greater the severity, the greater the underlying genetic liability and, hence, the greater the proportion of affected relatives. Endometriosis was more severe in familial cases, which also lessens the likelihood that the presence of an affected family member led to the identification of an affected relative merely because of a higher index of clinical suspicion.

The other formal explanation, and perhaps the most likely (i.e., not all endometriosis is the same disorder), is genetic heterogeneity. One or more forms of endometriosis might be Mendelian despite the larger proportion being nongenetic or polygenic. This has proved to be the likely explanation for peptic ulcer and other adult-onset disorders. No studies have shown HLA associations with endometriosis,24,25,26 which is more suggestive, however, of polygenic/multifactorial inheritance than genetic heterogeneity.

As noted, genome-wide genetic analysis is underway by several groups seeking to localize the various genes paramount to the etiology of endometriosis. Kennedy and colleagues15,17 are using sibling-pair analysis with polymorphic DNA markers. Identification of multiple nonlinked genes would be consistent with either polygenic inheritance or genetic heterogeneity. Several regions of exclusion have been identified by Kennedy and colleagues,15 but no linkage has been observed. This lack of success could reflect inaccuracies in diagnosis. In Icelandic women, a “suggestive locus” was found on 9q that is not in the region of the galactose-l-phosphate uridyl transferase (GALT) gene.19

MOLECULAR BASIS

Initial steps are underway to determine the molecular basis of endometriosis. One vexing problem has been difficulty in studying pure endometriosis tissue, necessary to avoid analysis of tissue samples in which normal endometrium or connective tissues are admixed with endometriotic tissue. Analysis of the normal tissue should prove genetically normal and may possibly explain the failure of Dangel and colleagues27 to find cytogenetic abnormalities in any of 45 endometrial implants. Similarly, Vercellini and coworkers28 failed to find ras oncogene- and p53 tumor suppressor gene-specific mutations in ectopic and eutopic endometrial tissue biopsy specimens from 10 women with severe endometriosis. Techniques are now being used that offer greater confidence for the genetic information truly being reflective of endometriosis-derived tissue. Our group has used touch preparations to study endometriotic tissues, in which histology can be confirmed in a mirror-image micrograph. Using fluorescence in situ hybridization with chromosome-specific probes, monosomy 16 and 17 and trisomy 11 cells were found.29 We also found chromosome 17 monosomic cells consistently in each of 8 endometriotic samples.30 Various chromosome abnormalities, including tetrasomy 17, also were observed in a human endometriosis-derived established cell line by Bouquet de Joliniere and colleagues.31 This French team has used comparative genome hybridization to find 1q+ , 4q-, 11p-, 13q-; loss of 9, 12, and 18; and amplification of 6p.32 Together, these studies provide evidence that acquired chromosome-specific alterations may be involved in endometriosis, possibly reflecting clonal expansion of chromosomally abnormal cells.

A polymorphism in the GALT gene—an adenine-to-guanine transition in exon 10, substituting aspartate for asparagine (N314D)—was found to be associated with endometriosis by Cramer and coworkers33 but not by Morland and coworkers34 and Hadfield and coworkers.35

In endometriosis, we have hypothesized that the chromosomal pattern of aberrations combined with the invasive nature of the disorder parallels between endometriosis and neoplasia.36 Pathogenesis of neoplasia is now accepted as involving clonal expansion of a progenitor cell, giving rise to selective advantage. By this scenario, two “hits” (mutational events) are necessary; both may be somatic mutations or one may be germline and the other somatic. Relevant to this hypothesis is that monoclonal cell expansion in endometriosis has been observed.37,38 Some investigators now speculate that endometrioid ovarian cancers probably arise by the malignant transformation of endometriotic implants.39 Although the frequency of malignant transformation is less than 1%,40,41 there is clear association of endometriosis with certain “endometrioid” malignancies.42,43,44 Cancers arising from endometriosis typically are divided into two main groups based on site: ovarian and extraovarian. Ovarian cancers account for more than 75% of the cases, consisting predominantly of endometrioid (70%) and clear-cell (14%) carcinoma. Of the extraovarian tumors, approximately 66% are endometrioid carcinomas localized to the rectovaginal septum (most common), uterus, Fallopian tubes, rectum, or bladder. Therefore, in the search for the genes involved in endometriosis, initial screening of chromosomal or gene-specific alterations or both identified in these cancers is warranted in endometriotic cells.

Jiang and colleagues45 have reported using microdissected endometriotic glands and stroma from archival tissue to investigate whether loss of heterozygosity (LOH) in chromosomal regions associated with ovarian carcinomas occurs in late-stage endometriosis. They showed monoclonal origin in endometriotic cysts and provided evidence of LOH involving chromosomes 9p, 11q, and 22q compared with normal genomic DNA. In a subsequent study, the same authors show common genetic alterations in nine of 11 cases in which ovarian carcinoma had arisen within or adjacent to endometriosis.46 They observed alterations in chromosome arms 5q, 6q, 9p, 11q, and 22q to be common in 25% to 30% of cases involving endometriosis with associated carcinoma. In one endometriosis sample, mutation in the p53 gene at codon 220 (Tyr to Cys) was observed. Similarly, we have reported preliminary findings of chromosome 17 alterations, namely LOH involving 17q in 4 (30%) of 12 cases47 and monosomy 17 in all 8 cases.30 In both of these studies, endometriotic DNA or cells, respectively, were analyzed and compared with matched “normal” tissue from patients confirmed to have stage III or IV disease. Therefore, genetic alterations associated with ovarian endometrioid cancers may be involved in the development of endometriosis.

Further support of the hypothesis that ovarian endometrioid cancers arise through malignant transformation of endometriotic lesions stems from recent evaluation of DNA alterations in the subtypes of epithelial ovarian cancers. Obata and coworkers48 reported mutations in the tumor suppressor PTEN gene on chromosome 10q23 in endometrioid but not serous or mucinous epithelial ovarian tumors. They analyzed more than 81 ovarian tumors, including 34 endometrioid, 29 serous, 10 mucinous, and 8 clear-cell tumors for LOH on 10q23 and mutations in PTEN. Although LOH was common among the endometrioid (43%) and serous (28%) tumors, somatic mutations involving PTEN in the remaining allele was observed only in the endometrioid (21%) tumors. These results show that the developmental pathways of the 3 epithelial ovarian cancer subtypes (serous, mucinous, and endometrioid) appear to be different and that somatic mutations in PTEN may represent early events in the transformation of benign endometriotic cells to malignancy. The PTEN protein is believed to function as a tyrosine phosphatase and play a role in signal transduction. Interestingly, other studies have shown PTEN mutations to be common in endometrial cancers in which microsatellite instability is detected.49,50

Immunocytochemical studies have also shown high protein levels of various proto-oncogene expression in endometriotic tissue compared with normal endometrium, including c-myc, c-fms, c-erbB-1/-2, and ras.51,52 Amplification on the short arm of chromosome 6 (6p) has also been seen.32 However, none of several potential candidate genes on 6p were overexpressed. These results suggest that altered proto-oncogene expression may be involved in disregulated growth and differentiation of endometriotic cells.

The bcl-2 gene is a member of the Bcl-2 gene family, and overexpression of this gene leads to a decreased rate of cell death.53 This gene is considered to play a role in the normal endometrium cycle by regulating cellular homeostasis and apoptosis; increased expression is detected in the proliferative endometrial phase but not in the secretory phase.54 Although several studies have examined the expression of bcl-2 in endometrial carcinomas and hyperplasia, the results have been controversial.55 In a recent study, Watanabe and coworkers56 reported bcl-2 overexpression in ectopic endometrial lesions by immunohistochemical staining, indicating that endometriotic cells fail to undergo apoptosis. Dmowski and colleagues57 have also reported decreased apoptosis of endometrial cells in endometriosis.

ENVIRONMENTAL COMPONENT

That only some women have endometriosis implies that there is increased susceptibility to development of disease among certain women. Individual susceptibility is not only influenced by genetic background but also by the interaction of genes with environmental factors. Dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin; TCDD) and dioxin-like compounds (DLCs) (e.g., polychlorinated biphenyls [PCBs]) have been implicated as factors involved in the development of endometriosis.58 The major route of human exposure to dioxin and DLCs is through diet. These compounds are hydrophobic and resistant to metabolic degradation, with an estimated half-life of 7 years in humans. Consequently, they accumulate to high levels in lipids and membranes, being released slowly into the blood. In addition to well-described toxic effects, dioxin has adverse effects on the female reproductive system. Dioxin administration severely reduced the reproductive success and estrous cycling in rodents and nonhuman primates59,60 and antagonized estrogen-induced increases in uterine weights and endometrial development in mice.61 Using rhesus monkeys, Rier and coworkers62 were first to show the direct relationship between dioxin and endometriosis. Autopsy evaluation of animals exposed daily for 5 years to 5 or 25 parts-per-trillion (ppt) of dioxin in their food showed widespread peritoneal endometriosis in 71% and 86% of animals, respectively. Among the control group, endometriosis was observed in only two (33%) animals; this is similar to the spontaneous endometriosis rate in colonies of rhesus monkeys. In humans, there is increasing epidemiologic evidence of the effects of dioxin. Gerhard and Runnebaum63 reported higher levels of PCBs in 28 patients with endometriosis compared with 441 unaffected women in a population of infertile women. Koninckx and colleagues64 indicated that the incidence of endometriosis in Belgium is approximately 60% to 80% in infertile women and pain, one of the highest reported incidences in the world. In 1989, the World Health Organization65 reported dioxin concentrations in breast milk of Belgium women to be among the highest in the world. Increased concentration of dioxin in breast milk may reflect the high dioxin accumulation in women, possibly explaining the high incidence of endometriosis in these women. More recently, Mayani and coworkers66 measured the concentration of dioxin in the peripheral blood of 44 women with endometriosis compared with 35 control subjects. Dioxin concentrations of 0.6 to 1.2 ppt were detected in 18% of affected cases compared with 0.4 ppt in one (3%) control case. Together, these studies suggest that dioxin and DLCs may play a role in the development of endometriosis in humans.

The phase II conjugating enzymes usually function to inactivate carcinogenic and procarcinogenic compounds. Among the phase II enzymes, two have been studied extensively, GSTs and NAT2, and are considered important cancer susceptibility genes. Both the GSTM1 and GSTT1 genes are polymorphic with null alleles that can be detected by polymerase chain reaction-based methods.67,68 In the study of 84 cases of epithelial ovarian cancer, Sarhanis and coworkers69 reported an influence of the GSTM1 and GSTT1 null alleles on increased p53 expression. The authors proposed that the GSTM1 and GSTT1 are critical in the detoxification of the products of oxidative stress produced during the repair of the ovarian epithelium. Thus, homozygous null alleles in both genes may function synergistically, causing inefficient detoxification of intermediates produced during stress that increase damage to various genes in the host cell, including p53, resulting in persistent expression of mutant protein. A recent study has shown a possible role of the homozygous GSTM1 null allele with the development of endometriosis in 86% (n = 50) of cases compared with 45.8% (n = 72) of control unaffected women (p < .0001).70 Our preliminary results of an association of M1/M2 NAT2 slow-acetylator genotype provide further evidence that heritable allelic differences in drug-metabolizing enzymes may play an important role in the development of endometriosis.71

REFERENCES

1

Clement PB: Pathology of endometriosis. Pathol Annu 25: 245–295, 1990

 

2

American Fertility Society: Revised American Fertility Society classification of endometriosis: 1996. Fertil Steril 67:817–821, 1997

 

3

Lui TDY: Endometriosis: Its association with retrograde menstruation, dysmenorrhea and tubal pathology. Br J Obstet Gynecol 93: 859–864, 1986

 

4

TeLinde RW, Scott RB: Experimental endometriosis. Am J Obstet Gynecol 60: 1147–1173, 1960

 

5

Sampson JA: Peritoneal endometriosis due to menstrual dissemination of endometrial tissues into the peritoneal cavity. Am J Obstet Gynecol 14: 422–469, 1927

 

6

Koninckx PR: Is mild endometriosis a condition occurring intermittently in all women? Hum Reprod 9: 2202–2205, 1994

 

7

Ranney B: Endometriosis: IV. Hereditary tendency. Obstet Gynecol 37: 734–737, 1971

 

8

Simpson JL, Elias S, Malinak LR et al: Heritable aspects of endometriosis: I. Genetic studies. Am J Obstet Gynecol 137: 327–331, 1980

 

9

Malinak LR, Buttram VC, Elias S et al: Heritable aspects of endometriosis II Clinical characteristics of familial endometriosis. Am J Obstet Gynecol 137: 332, 1980

 

10

Lamb K, Hoffmann RG, Nichols TR: Family trait analysis: A case-control study of 43 women with endometriosis and their best friends. Am J Obstet Gynecol 154: 596, 1986

 

11

Moen MH, Magnus P: The familial risk of endometriosis. Acta Obstet Gynecol Scand 72: 560–564, 1993

 

12

Moen MH: Endometriosis in monzygotic twins. Acta Obstet Gynecol Scand 73: 59–62, 1994

 

13

Coxhead D, Thomas EJ: Familial inheritance of endometriosis in a British population. A case control study. J Obstet Gynecol 13: 42, 1993

 

14

dos Reis RM, de Sa MF, de Moura MD et al: Familial risk among patients with endometriosis. J Assist Reprod Genet 16: 500–503, 1999

 

15

Kennedy SH, Mardon HJ, Barlow DH: Familial endometriosis. J Assist Reprod Genet 12: 32, 1995

 

16

Kennedy SH, Hadfield R, Mardon HJ et al: Age of onset of pain symptoms in non-twin sisters concordant for endometriosis. Hum Reprod 11: 101–103, 1996

 

17

Kennedy SH: The genetics of endometriosis. J Reprod Med 43: 263–268, 1998

 

18

Hadfield RM, Mardon HJ, Barlow DH et al: Endometriosis in monozygotic twins. Fertil Steril 68: 941, 1997

 

19

Stefansson H, Geirsson RT, Guanason GA et al: A genome-wide search for endometriosis genes in Icelandic patients. Am J Hum Genet 63: A311, 1998

 

20

Kennedy S, Hadfield R, Westbrook C et al: Magnetic resonance imaging to assess familial risk in relatives of women with endometriosis. Lancet 352: 1440, 1998

 

21

Kennedy SH, Weeks DE, Laird E et al: The use of MRI in genetic studies of endometriosis. Am J Med Genet 71: 371–372, 1997

 

22

Treloar SA, O'Connor DT, O'Connor VM et al: Genetic influences on endometriosis in an Australian twin sample. Fertil Steril 71: 701–710, 1999

 

23

Hinson JM Jr, Brigham KL, Daniell J: Catamenial pneumothorax in sisters. Chest 80: 634, 1981

 

24

Simpson JL, Malinak LR, Elias S et al: HLA association in endometriosis. Am J Obstet Gynecol 148: 395–397, 1984

 

25

Moen HL, Bratlie A, Moen T: Distribution of HLA-antigens among patients with endometriosis. Acta Obstet Gynecol Scand (Suppl) 123: 25–27, 1984

 

26

Maxwell C, Kilpatrick DC, Haining R et al: No HLA-DR specificity is associated with endometriosis. Tissue Antigens 34: 145–147, 1989

 

27

Dangel A, Medchill MT, Davis G et al: Cytogenetic studies in endometriosis tissue. Cancer Genet Cytogenet 78: 172, 1994

 

28

Vercellini P, Trecca D, Oldani S et al: Analysis of p53 and ras gene mutations in endometriosis. Gynecol Obstet Invest 38: 70–71, 1994

 

29

Shin JC, Ross HL, Elias S et al: Detection of chromosomal aneuploidy in endometriosis by multi-color fluorescence in situ hybridization (FISH). Hum Genet 100: 401–406, 1997

 

30

Kosugi Y, Elias, S, Malinak RL et al: Increased heterogeneity of chromosome 17 aneuploidy in endometriosis. Am J Obstet Gynecol 180: 792, 1999

 

31

Bouquet de Joliniere J, Validire P, Canis M et al: Human endometriosis-derived permanent cell line (FbEM-1): Establishment and characterization. Human Reprod Update 3: 117–123, 1997

 

32

Gogusev, Bouquet de Joliniere J, Doussau M et al: Detection of genetic abnormalities in human endometriosis by comparative genomic hybridization. Presented at American Society of Reproductive Medicine, Toronto, Canada, 1998

 

33

Cramer DW, Hornstein MD, Ng WG et al: Endometriosis associated with the N314D mutation of galactose-1-phosphate uridyl transferase (GALT). Mol Hum Reprod 2: 149, 1996

 

34

Morland SJ, Jiang X, Hitchcock A et al: Mutation of galactose-1-phosphate uridyl transferase and its association with ovarian cancer and endometriosis. Int J Cancer 77: 825, 1998

 

35

Hadfield RM, Manek S, Nakago S et al: Absence of a relationship between endometriosis and the N314D polymorphism of galactose-1-phosphate uridyl transferase in a UK population. Mol Hum Reprod 5: 990, 1999

 

36

Bischoff F, Simpson JL: Heritability and molecular genetic studies of endometriosis. Hum Reprod Update 6: 37–44, 2000

 

37

Jimbo H, Hitomi Y, Yoshikawa H et al: Evidence for monoclonal expansion of epithelial cells in ovarian endometrial cysts. Am J Pathol 150: 1173, 1997

 

38

Tamura M, Fukaya T, Murakami T et al: Analysis of clonality in human endometriotic cysts based on evaluation of X chromosome inactivation in archival formalin-fixed, paraffin-embedded tissue. Lab Invest 78: 213, 1998

 

39

Sainz de la Cueata R, Eichhorn J, Rice L et al: Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60: 238–244, 1996

 

40

Mostoufizadeh GH, Scully RE: Malignant tumor arising in endometriosis. Clin Obstet Gynecol 23: 951–963, 1980

 

41

Heaps JM, Nieberg RK, Berek JS: Malignant neoplasms arising in endometriosis. Obstet Gynecol 75: 1023–1028, 1990

 

42

De la Cueata R, Eichhorn J, Rice L et al: Histologic transformation of benign endometriosis to early epithelial ovarian cancer. Gynecol Oncol 60: 238, 1996

 

43

Vercellini P, Parazzini F, Bolis G et al: Endometriosis and ovarian cancer. Am J Obstet Gynecol 169: 181, 1993

 

44

McMeekin D, Burger R, Manetta A et al: Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol 59: 81, 1995

 

45

Jiang X, Hitchcock A, Bryan E et al: Microsatellite analysis of endometriosis reveals loss of heterozygosity at candidate ovarian tumor suppressor gene loci. Cancer Res 56: 3534–3537, 1996

 

46

Jiang X, Morland SJ, Hitchcock A et al: Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res 58: 1707–1711, 1998

 

47

Bischoff FZ, Ross HL, Nguyen DD et al: Loss of heterozygosity for chromosome 17 (p53) in endometriosis by molecular genetic and two-color FISH analysis. J Soc Gynecol Invest Suppl 4: 205A, 1997

 

48

Obata K, Morland SJ, Watson RH et al: Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58: 2095–2097, 1998

 

49

Peiffer S, Herzog T, Tribune D et al: Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 55: 1922–1926, 1995

 

50

Tashiro H, Blazes MS, Wu R et al: Mutations in PTEN are frequent in endometrial carcinoma, bur rare in other common gynecological malignancies. Cancer Res 57: 3935–3940, 1997

 

51

Schenken RS, Johnson JV, Riehl RN: C-myc proto-oncogene polypeptide expression in endometriosis. Am J Obstet Gynecol 164: 1031–1037, 1991

 

52

Bergqvist A, Borg A, Ljungberg O: Proto-oncogenes in endometriotic and endometrial tissue. Ann NY Acad Sci 626: 276–283, 1991

 

53

Yang E, Korsmeyer S: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88: 386–401, 1996

 

54

Lu OL, Poulsom R, Wong L et al: Bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol 169: 431–437, 1993

 

55

Henderson G, Brown K, Perkins S et al: bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol 9: 430–438, 1996

 

56

Watanabe H, Kanzaki H, Narukawa S et al: Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis. Am J Obstet Gynecol 176: 360–368, 1997

 

57

Dmowski W, Gebel H, Braun DP: Decreased apoptosis and sensitivity to macrophage mediated cytolysis of endometrial cells in endometriosis. Hum Reprod Update 4: 696–701, 1998

 

58

Zeyneloglu HB, Arici A, Olive DL: Environmental toxins and endometriosis. Obstet Gynecol Clin North Am 24: 307–329, 1997

 

59

Cummings AM, Metcalf JL: Induction of endometriosis in mice: A new model sensitive to estrogen. Reprod Toxicol 9: 233–238, 1995

 

60

Tryphonas H, Luster MI, Schiffman G et al: Effect of chronic exposure of PCB (Aroclor 1254) on specific and nonspecific immune parameters in the rhesus (Macaca mulatta) monkey. Fundam Appl Toxicol 16: 773–786, 1991

 

61

Johnson KL, Cummings AM, Birnbaum LS: Promotion of endometriosis in mice by polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls. Environ Health Prospect 105: 750–755, 1997

 

62

Rier SE, Martin DC, Bowman RE et al: Endometriosis in rhesus monkey (Macaca mulatta) following chronic exposure to 2,3,7,8-tetrachlorodibeno-p-dioxin. Fundam Appl Toxicol 21: 433–441, 1993

 

63

Gerhard I, Runnebaum B: The limits of hormone substitution in pollutant exposure and fertility disorders. Zentralbl Gynakol 114: 593–602, 1992

 

64

Koninckx PR, Braet P, Kennedy SH: Dioxin pollution and endometriosis in Belgium. Hum Reprod 9: 1001–1002, 1994

 

65

WHO Report: Levels of PCBs, PCDDs and PCDFs in breast milk: Result of WHO coordinated interlaboratory quality control studies and analytical field studies. WHO Environmental Series, 1989

 

66

Mayani A, Barel S, Soback S et al: Dioxin concentrations in women with endometriosis. Hum Reprod 12: 373–375, 1997

 

67

Lear J, Heagerty A, Smith A et al: Multiple cutaneous basal cell carcinomas: Glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour numbers and accrual. Carcinogenesis 17: 1891–1896, 1996

 

68

Hand P, Inskip A, Gilford J et al: Allelism at the glutathione S-transferase GSTM3 locus: Interactions with GSTM1 and GSTT1 as risk factors for astrocytoma. Carcinogenesis 17: 1919–1922, 1996

 

69

Sarhanis P, Redman C, Perrett C et al: Epithelial ovarian cancer: influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression. Br J Cancer 74: 1757–1761, 1996

 

70

Baranova H, Bothorishvilli R, Canis M et al: Glutathione S-transferase M1 gene polymorphism and susceptibility to endometriosis in a French population. Mol Hum Reprod 3: 775–780, 1997

 

71

Bischoff FZ, Marquez-Do D, Kosugi Y et al: Association of N-acetyltransferase 2 (NAT2) genetic polymorphism resulting in decreased capacity to detoxify aromatic amines in women with endometriosis. J Soc Gynecol Invest 5: 111A, 1998

 
Back to Top